‘Data Protection’: Needs A Clear Direction…But Is It An IPR Issue?

The terminologies ‘Data Exclusivity’ and ‘Data Protection’ are quite often used interchangeably by many, creating a great deal of confusion on the subject. However, in a true sense these are quite different issues having critical impact on public health interest … Continue reading

The Game Changer: Effective transition from ‘blockbuster’ to an integrated ‘niche buster’ plus ‘generic drugs’ business model

Since quite some time global pharmaceutical majors have been operating within the confines of high risk – high reward R&D based business model with blockbuster drugs (annual sales of over US$ 1 billion). Blockbuster brands, mostly in the chronic-care segments … Continue reading

EU-FTA, TRIPS-Plus provisions, Data Exclusivity, Public Interest and India

Business Standard in its January 27, 2011 edition reported, “Data Exclusivity still key hurdle to India-EU FTA” Before deliberating on this important issue of “Free Trade Agreement (FTA)”, let me touch upon very briefly, for the benefit of all concerned, … Continue reading